Hongwei Du
YOU?
Author Swipe
View article: Efficient defluoridation of high-fluoride water using rare earth-based adsorbents: adsorption performance, mechanism, and kinetics
Efficient defluoridation of high-fluoride water using rare earth-based adsorbents: adsorption performance, mechanism, and kinetics Open
This study investigated the adsorption behaviour of fluoride ions from fluorine-containing solutions at a defined concentration using Ce3+ and hydrogen peroxide. The influences of adsorption time, solution pH, adsorbent dosage, …
View article: 3D bioprinted human-scale intestine models for physiological and microbial insights through fluid-driven heterogeneity
3D bioprinted human-scale intestine models for physiological and microbial insights through fluid-driven heterogeneity Open
The small intestine’s intricate structure enables vital functions such as nutrient absorption, microbial defense, and barrier protection, yet replicating its complexity in vitro remains a substantial challenge. We engineered a three-dimens…
View article: Activation Characteristics and Aluminum Recovery from Coal Gangue: Structure–Phase–Reactivity Relationships Revealed by Thermal Analysis, Kinetics, and Acid Leaching
Activation Characteristics and Aluminum Recovery from Coal Gangue: Structure–Phase–Reactivity Relationships Revealed by Thermal Analysis, Kinetics, and Acid Leaching Open
View article: Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma
Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma Open
View article: TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile
TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile Open
CAR‐T therapy faces significant challenges in solid tumors, including the shortage of targetable antigen and the immunogenicity of CAR molecules. Here, TSHR is identified as specifically expressed in DTC, but absent in other normal tissues…
View article: Phase Transformation and Si/Al Leaching Behavior of High-Silica–Alumina Coal Gangue Activated by Sodium-Based Additives
Phase Transformation and Si/Al Leaching Behavior of High-Silica–Alumina Coal Gangue Activated by Sodium-Based Additives Open
High-silica–alumina coal gangue is rich in kaolinite, quartz, and other mineral components. The potential for resource utilization is huge, but the silica–aluminate structure is highly stable, and it is difficult to achieve efficient disso…
View article: Protocol for embedded 3D bioprinting of arterial models with customized contractile and metabolic functions
Protocol for embedded 3D bioprinting of arterial models with customized contractile and metabolic functions Open
View article: Corrigendum to “Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors” [Pharmacol. Res. 210 (2024) 107506]
Corrigendum to “Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors” [Pharmacol. Res. 210 (2024) 107506] Open
View article: Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors
Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors Open
Lack of biopsies after treatment, especially in solid tumors, restricts the understanding of chimeric antigen receptor (CAR)-T cells -related characteristic in vivo, thus hindering the development of strategies to improve CAR-T cells effic…
View article: Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3 expression is retained on THP1 cells and patient-derived AML blasts after B7-H3.CAR-T treatment
View article: Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in a patient-derived xenograft model of AML.
View article: Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Supplemental Methods
View article: Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Purpose:The development of safe and effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant expression of most AML-associated surface antigens on normal myeloid …
View article: Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Purpose:The development of safe and effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant expression of most AML-associated surface antigens on normal myeloid …
View article: Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in additional xenograft model using OCI-AML2 cells
View article: Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in a patient-derived xenograft model of AML.
View article: Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3 expression is retained on THP1 cells and patient-derived AML blasts after B7-H3.CAR-T treatment
View article: Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Correlation of B7-H3 mRNA expression with AML features in existing datasets.
View article: Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Correlation of B7-H3 mRNA expression with AML features in existing datasets.
View article: Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Supplemental Methods
View article: Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in additional xenograft model using OCI-AML2 cells
View article: Table S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Table S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Clinical details associated with primary AML patient samples
View article: Figure S3 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S3 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Comparison of B7-H3 expression with B7-H3.CAR-T cytotoxicity.
View article: Figure S3 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S3 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Comparison of B7-H3 expression with B7-H3.CAR-T cytotoxicity.
View article: Table S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Table S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Clinical details associated with primary AML patient samples
View article: STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity
STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity Open
STING is an innate immune sensor for immune surveillance of viral/bacterial infection and maintenance of an immune‐friendly microenvironment to prevent tumorigenesis. However, if and how STING exerts innate immunity‐independent function re…
View article: Treatment of glutaric aciduria type I (GA-I) via intracerebroventricular delivery of GCDH
Treatment of glutaric aciduria type I (GA-I) via intracerebroventricular delivery of GCDH Open
View article: Study on the Effect of PDA-PLGA Scaffold Loaded With Islet Cells for Skeletal Muscle Transplantation in the Treatment of Diabetes
Study on the Effect of PDA-PLGA Scaffold Loaded With Islet Cells for Skeletal Muscle Transplantation in the Treatment of Diabetes Open
At present, islet cells transplantation was limited by the way in which islet cells are implanted into the body, their ability to adapt to the microenvironment and the maintenance time for relieving diabetic symptoms. In order to solve thi…
View article: Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration
Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration Open
View article: Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors
Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors Open
Background Adoptive T-cell transfer has become an attractive therapeutic approach for hematological malignancies but shows poor activity against large and heterogeneous solid tumors. Interleukin-12 (IL-12) exhibits potent antitumor efficac…